Chimerix Investor Conference Presentation Deck

Endpoints 7 Primary Endpoint Overall response rate by RANO-HGG criteria Secondary Endpoints Overall response rate by RANO-Low Grade Glioma (LGG) criteria Duration of response¹ ● ● ● ● ● ● ● Time to response¹ Best overall response¹ Disease Control Rate¹ Progression-free survival¹ Overall survival Corticosteroid response rate Performance status response rate Analysis First 50 patient enrolled who meet eligibility for integrated efficacy analysis² ● Censored for all endpoints except overall survival upon eligibility criteria initiation of any additional anti-cancer therapy ¹Assessed by RANO-HGG and RANO-LGG criteria with dual-reader blinded independent central review (BICR). 2As discussed and prespecified with regulatory authorities

View entire presentation